OS foi o resultado primário do estudo SARAH. As microesferas de resina SIR-Spheres® Y-90 não mostraram uma melhora significativa no SG sobre o sorafenibe.

Apesar de 22% dos pacientes no braço SIRT não receberem microesferas de resina SIR-Spheres Y-90, a sobrevida global média por intenção de tratar (ITT) foi de 8,0 vs. 9,9 meses (HR: 1,15 [95% CI: 0,94- 1,41], p = 0,18) para SIRT vs sorafenib. Além disso, para pacientes que receberam microesferas de resina SIR-Spheres Y-90 ou sorafenibe de acordo com o protocolo SARAH, a mediana da OS foi 9,9 vs. 9,9 meses (HR: 0,99 [IC 95%: 0,79-1,24]; p = 0,92).


Reimpresso da The Lancet Oncology, vol. 18, Vilgrain V, Pereira H., Assenat E et al. Eficácia e segurança da radioterapia interna seletiva com microesferas de resina de ítrio-90 comparada ao sorafenibe em carcinoma hepatocelular localmente avançado e inoperável (SARAH): um estudo de fase 3 controlado randomizado, aberto, Páginas 1624-1636., Copyright (2017), com permissão da Elsevier.

Vilgrain V et al.  Lancet Oncol 2017; 18: 1624–36.




Now leaving sirtex.com

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.

Continue

×

Now leaving sirtex.com

You are about to leave the Sirtex Website. This link is provided to you as a service and will take you to the Sirtex Virtual Booth.

Sirtex is responsible for the content of the Virtual Booth, which is hosted on a website maintained by a third-party. Except for Sirtex’s Virtual Booth experience, please be aware that Sirtex takes no responsibility for the other content of these external sites, nor do we endorse, warrant, or guarantee the products, services or information described or offered on other internet sites.

Continue

×

You are now leaving your current sirtex.com region

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.

Continue

×